AI assistant
Biocon Ltd. — Call Transcript 2025
Nov 4, 2025
61176_rns_2025-11-04_173bbb65-d6e1-4c56-9365-e9a1f160f1bf.pdf
Call Transcript
Open in viewerOpens in your device viewer
==> picture [132 x 53] intentionally omitted <==
Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T: 91 80 2808 2808 F: 91 80 2852 3423 CIN : L24234KA1978PLC003417
www.biocon.com
BIO/SECL/TG/2025-26/112
November 04, 2025
To, To, The Secretary The Secretary BSE Limited National Stock Exchange of India Limited Department of Corporate Services Corporate Communication Department Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra Kurla Complex Dalal Street, Mumbai – 400 001 Mumbai – 400 050 Scrip Code – 532523 Scrip Symbol - Biocon
Dear Sir/Madam,
Subject: Intimation for Earnings Conference Call for analysts/investors for Q2 FY 2025-26 Financial Results
Pursuant to Regulation 30(6) of the SEBI Listing Regulations, we wish to inform you that Company will organize an Earnings Conference Call for analysts/investors for Q2 FY 2025-26 financial results, on Wednesday, November 12, 2025. The details of the same are enclosed herewith.
The above-mentioned information will also be available on website of the Company at www.biocon.com.
Request you to take the above intimation on record.
Thanking You,
For Biocon Limited
RAJESH Digitally signed by RAJESH UMAKANT UMAKANT SHANOY Date: 2025.11.04 SHANOY 14:47:22 +05'30'
Rajesh U. Shanoy Company Secretary and Compliance Officer Membership No.: ACS 16328
Encl: as above
20th K.M. Hosur Road, Electronics City, Bengaluru 560 100
November 4, 2025
Biocon's Q2 FY 2025-26 Earnings Conference Call
At 09:00 hrs. IST on November 12, 2025
The management team of Biocon Limited (BSE code: 532523, NSE ID: BIOCON) will organize a conference call for Analysts and Investors following the announcement of financial results for the quarter ending September 30, 2025. The call will be conducted over a Webcast.
| Conference Call Details | Conference Call Details |
|---|---|
| Date | Wednesday, November 12, 2025 |
| Time | 09:00 hrs IST |
| Registration Link | Click here |
| Recording | • Audio recording will be made available within 24 hrs from the end of the call • Video recording will be made available within 48 hrs from the end of the call • Access the recordings on the Company website (Biocon > Investors > Financial Information > Earnings Call Recordings) |
| Conference Call Transcript | Will be made available on the Company website (Biocon > Investors > Financial Information > Earnings Call Transcripts) |
Note: Participants are requested to join 10 minutes before the scheduled start time of the call.
For further information please contact:
Saurabh Paliwal
Investor Relations – Biocon Limited P: +91 80 2808 2040/ +91 95383 80801 E: [email protected]
Safe Harbor: Certain statements that may be made in the conference call may be forward-looking based on management's current expectations and beliefs concerning future developments and their potential effects upon Biocon and its subsidiaries/ associates. These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from our expectations include, amongst other: general economic and business conditions in India and overseas, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian and global biotechnology and pharmaceuticals industries, changes in political conditions in India and overseas, and changes in the foreign exchange control regulations in India. Neither Biocon, nor our directors, nor any of our subsidiaries/associates assume any obligation to update any forward-looking statement contained in the conference call.